Questions about this study?
The HopeStage team will email you.
Get research updatesThis historical record does not confirm current site availability.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This is historical registry information. What is the current study status and protocol?
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease
The HopeStage team will email you.
Austria · Belgium · Portugal
A listed location does not confirm current availability.
The study sponsor is Acadia Pharmaceuticals Inc.
The historical registry lists this study as not recruiting.
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me